Skip to Main Content

Paper Details

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.
Multiple Sclerosis Journal
50
2019
Alemtuzumab, CAMMS03409, IFNB-1a, Lymphocyte, MS, Multiple Sclerosis, SC IFNB-1a, acyclovir, alemtuzumab, herpetic infections, mucocutaneous herpetic infections, patients, subcutaneous interferon beta-1a, upper respiratory tract infections, urinary tract infections
Author NameAffiliation
Hans-Peter HartungHeinrich-Heine-University Dusseldorf
Krzysztof SelmajMedical University of Lodz
Howard L WeinerThe Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital
  • 1 - 3

Datasets

Release 1.2